Rilvegostomig is under clinical development by AstraZeneca and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC). According to GlobalData, Phase II drugs for Head And Neck Squamous Cell Carcinoma (HNSC) have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Rilvegostomig’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Rilvegostomig overview

Rilvegostomig (AZD-2936) is under development for the treatment of metastatic solid tumors including biliary tract cancer, ovarian cancer, breast cancer, endometrial cancer, advanced or metastatic squamous or metastatic non-squamous non-small cell lung carcinoma, squamous or non-squamous non-small cell lung cancer, head and neck squamous cell carcinoma, oral cavity (mouth) cancer, oropharyngeal cancer, hepatocellular carcinoma, hypopharyngeal cancer, laryngeal cancer and locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, cholangiocarcinoma (biliary tract cancer), bladder cancer and gallbladder cancer. It is administered through intravenous route. The therapeutic candidate is a bi-specific monoclonal antibody acts by targeting T cell immunoreceptor with Ig and ITIM domains (TIGIT) and programmed cell death protein 1 (PD1). It is derived from COM902 (anti-TIGIT antibody).

AstraZeneca overview

AstraZeneca is a biopharmaceutical company, that focuses on the discovery, production, and commercialization of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa, and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.

For a complete picture of Rilvegostomig’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 12 April 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.